These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28049253)

  • 1. Prostate Cancer in a Patient with a Family History of BRCA Mutation: a Case Report and Literature Review.
    Song WH; Kim SH; Joung JY; Park WS; Seo HK; Chung J; Lee KH
    J Korean Med Sci; 2017 Feb; 32(2):377-381. PubMed ID: 28049253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germline BRCA mutation in male carriers-ripe for precision oncology?
    Leão RRN; Price AJ; James Hamilton R
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):48-56. PubMed ID: 29242595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
    Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
    Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing.
    Mitri ZI; Jackson M; Garby C; Song J; Giordano SH; Hortobágyi GN; Singletary CN; Hashmi SS; Arun BK; Litton JK
    Oncologist; 2015 Jun; 20(6):593-7. PubMed ID: 25948675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate Cancer Screening in a New Era of Genetics.
    Cheng HH; Pritchard CC; Montgomery B; Lin DW; Nelson PS
    Clin Genitourin Cancer; 2017 Dec; 15(6):625-628. PubMed ID: 28697982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for familial and hereditary prostate cancer.
    Lynch HT; Kosoko-Lasaki O; Leslie SW; Rendell M; Shaw T; Snyder C; D'Amico AV; Buxbaum S; Isaacs WB; Loeb S; Moul JW; Powell I
    Int J Cancer; 2016 Jun; 138(11):2579-91. PubMed ID: 26638190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica.
    Gutiérrez Espeleta GA; Llacuachaqui M; García-Jiménez L; Aguilar Herrera M; Loáiciga Vega K; Ortiz A; Royer R; Li S; Narod SA
    Clin Genet; 2012 Nov; 82(5):484-8. PubMed ID: 21895635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA2 mutation screening is clinically relevant in breast and early prostate cancer families.
    Azzouzi AR; Stoppa-Lyonnet D; Roupret M; Larre S; Mangin P; Cussenot O
    Int J Urol; 2007 May; 14(5):445-6. PubMed ID: 17511731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Searching for candidate genes in familial BRCAX mutation carriers with prostate cancer.
    Hunter SM; Rowley SM; Clouston D; ; Li J; Lupat R; Krishnananthan N; Risbridger G; Taylor R; Bolton D; Campbell IG; Thorne H
    Urol Oncol; 2016 Mar; 34(3):120.e9-16. PubMed ID: 26585945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort.
    Ishiyama Y; Shimbo M; Iizuka J; Deshpande G; Tanabe K; Hattori K
    PLoS One; 2020; 15(12):e0244149. PubMed ID: 33351846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families.
    Thorne H; Willems AJ; Niedermayr E; Hoh IM; Li J; Clouston D; Mitchell G; Fox S; Hopper JL; ; Bolton D
    Cancer Prev Res (Phila); 2011 Jul; 4(7):1002-10. PubMed ID: 21733824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer in a man with a BRCA2 mutation and a personal history of bilateral breast cancer.
    Singer CF; Rappaport-Fuerhauser C; Sopik V; Narod SA
    Clin Genet; 2015 Aug; 88(2):187-9. PubMed ID: 25112434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
    Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
    Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel germline BRCA2 mutation in a Chinese patient with prostate cancer sensitive to platinum chemotherapy: a case report.
    Jiang L; Bai Z; Zhu S; Zhao T; Yang Y; Li Z; Chen D; Wu Z; Wang Y; Zhou F; Li Y
    BMC Urol; 2021 Aug; 21(1):114. PubMed ID: 34425813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relevance of BRCA genetics to prostate cancer pathogenesis and treatment.
    Sundararajan S; Ahmed A; Goodman OB
    Clin Adv Hematol Oncol; 2011 Oct; 9(10):748-55. PubMed ID: 22252577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations.
    Maier C; Herkommer K; Luedeke M; Rinckleb A; Schrader M; Vogel W
    Prostate; 2014 Oct; 74(14):1444-51. PubMed ID: 25111659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
    Gayther SA; de Foy KA; Harrington P; Pharoah P; Dunsmuir WD; Edwards SM; Gillett C; Ardern-Jones A; Dearnaley DP; Easton DF; Ford D; Shearer RJ; Kirby RS; Dowe AL; Kelly J; Stratton MR; Ponder BA; Barnes D; Eeles RA
    Cancer Res; 2000 Aug; 60(16):4513-8. PubMed ID: 10969800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
    Willems-Jones A; Kavanagh L; Clouston D; Bolton D; ; Fox S; Thorne H
    BJU Int; 2012 Dec; 110(11 Pt C):E1181-6. PubMed ID: 23035815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.
    Riahi A; Ghourabi ME; Fourati A; Chaabouni-Bouhamed H
    Breast Cancer; 2017 Mar; 24(2):238-244. PubMed ID: 27025497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.